


1/12







Application No.: N/A Customer No.: 25291
Inventors: Anthony F. Hadfield, etal
Ittorney Docket No.: AM100463
itle: Novel Succinate Salt of O-Desmethyl-Venlafax

3/12











5/12





looping and location

: Novel Succinate Salt of O-Desmethyl-Venlafaxine

7/12





FIG.7

Application No.: N/A Customer No.: 25291
Inventors: Anthony F. Hadfield, etal
ney Docket No.: AM100463
Novel Succinate Salt of O-Desmethyl-Venlafaxine

8/12



Application No.: N/A Customer No.: 25291
Inventors: Anthony F. Hadfield, etal
ttorney Docket No.: AM100463
le: Novel Succinate Salt of O-Desmethyl-Venlafaxin

9/12

## RAT JEJUNAL ABSORPTION OF ODV SUCCINATE AND INTERNAL MARKERS [ODV SUCCINATE] = 50 ug/ml, PERFUSION BUFFER, pH6.8





FIG.9


## INTESTINAL SITE-SPECIFIC ABSORPTION OF ODV SUCCINATE [ODV SUCCINATE] = 50 ug/ml, PERFUSION BUFFER, pH6.8



**FIG.10** 


Application No.: N/A Customer No.: 25291
Inventors: Anthony F. Hadfield, etal
rney Docket No.: AM100463
Novel Succinate Salt of O-Desmethyl-Venlafaxine

10/12



**FIG.11** 


INTESTINAL SITE-SPECIFIC ABSORPTION OF ODV FUMARATE [ODV FUMARATE] = 50 ug/ml, PERFUSION BUFFER, pH6.8



**FIG.12** 

Application No.: N/A Customer No.: 25291 Inventors: Anthony F. Hadfield, etal Attorney Docket No.: AM100463 Title: Novel Succinate Salt of O-Desmethyl-Venlage.

11/12



Application No.: N/A Customer No.: 25291

Inventors: Anthony F. Hadfield, etal

princy Docket No.: AM100463

S: Novel Succinate Salt of O-Desmethyl-Venlafaxing

12/12

MW 58.44 MW 18.02 + NaCl + H20 .NMe2 C16H25N02 MW 263.381 10N NaOH TO pH 9.6 MW 40.00 + NaOH NMe2 .HCI C<sub>16</sub>H<sub>26</sub>CINO<sub>2</sub> MW 299.84 오

<u>,</u>

FIG.14